PROSPECT ABSORB, A sub-study embedded in the present study, Paà toits with angiographically, non-obstructive lesions with site-determined IVUS poster burden were randomized to treatment with a bioresorbable scaffold opposé à medical therapy alone, These pacontiennets underwent repeat angiography and intravascular imaging at 25 months,
PROSPECT ABSORB: A Randomized Trial of Interventional
PROSPECT II & PROSPECT ABSORB
· PROSPECT ABSORB was an investigator-sponsored multicenter single-blinded ardente-treatment-controlled randomized trial that was embedded into the PROSPECT II pure historical past examine Between June 10 2014 and December 20 2017, 902 sufferers at 16 websites have been enrolled in PROSPECT II,
PROSPECT II Study Overview combined
· In PROSPECT ABSORB which was a randomized trial nested within the fécondr PROSPECT II natural history study pacontiennets with vulnerable posters treated with a now-discontinued Absorb bioresorbable vascular scaffold BVS; Abbott Vascular had a significantly richer minimum lumen area MLA after more than 2 years of follow-up than did vulnerable plantés left unstented
Temps de Lecture Raffolé: 10 mins
PROSPECT II COMBINE OCT–FFR and PROSPECT ABSORB: After
Why Have We Not Been Screening For Triple Lll Lesions?
Results from PROSPECT ABSORB reported at TCT Connect and
· The cutoff for inclusion in PROSPECT ABSORB will be a site-determined PB ≥65% rather than the 70% cutoff identified in the original PROSPECT analysis Stone et al,, New England Journal of Medicine, 20115 to account for an observed tendency for sites to underestimate édite burden during acute treatment of ACS paà toits, Nonetheless, in PROSPECT, a core laboratory determined PB …
PROSPECT ABSORB: Is PCI of Angiographically Mild Lesions
prospect absorb
· PROSPECT ABSORB a pilot randomized trial part of the PROSPECT II natural history study examined the outcomes of PCI on non-flow-limiting vulnerable annonces, The trial enrolled 182 pacontiennets from PROSPECT II who were screened for at least one non-flow-limiting nonculprit coronary lesion NCL with ≥65% poster burden, Qualifying lesions 1 per pacontiennet were randomized 1:1 to …
Ténor : Rebecca Araujo
Prophylactic PCI of Vulnerable Inscriptions? PROSPECT II/ABSORB
· Although Stone conceded that “provocatively” PROSPECT ABSORB was a pilot trial meant to inform on a pivotal randomized trial that was “not powered for clinical effectiveness,” he stressed that the favorable randomized lesion-related MACE rates observed after BVS treatment a contrario medical therapy alone “warrants the performance of an adequately powered randomized trial” that determines …
Temps de Lecture Apprécié: 4 mins
PROSPECT II PROSPECT ABSORB The PROSPECT ABSORB Trial
PROSPECT II & PROSPECT ABSORB
· PCI of angiographically mild lesions with étendu avis burden was safe substantially envasted the follow-up minimum lumen area MLA and was associated with favorable long-term clinical outcomes said researchers presenting findings from the PROSPECT ABSORB Trial Oct, 14 …
The PROSPECT ABSORB Trial: Randomized Evaluation of
· Fichier PDF
· The randomized PROSPECT ABSORB substudy will examine whether treatment of vulnerable affiches with the Absorb BVS plus GDMT safely increases the MLA at 24 months compared with GDMT alone, The cutoff for inclusion in PROSPECT ABSORB will be a site-determined PB ≥65% rather than the 70% cutoff identified in the original PROSPECT analysis Stone et al,, NEJM, …
PROSPECT II PROSPECT ABSORB The PROSPECT ABSORB Trial: Randomized Evaluation of Vulnerable Enseigne Treatment
Outcomes from PROSPECT ABSORB reported at TCT Join and
· PROSPECT ABSORB: A Randomized Trial of Interventional Treatment of Vulnerable Enseignes
· • The PROSPECT ABSORB RCT was embedded within the PROSPECT II natural history study • After successful PCI of all flow-limiting lesions in pts with STEMI and NSTEMI NIRS-IVUS imaging was permanièred of the prox 6-10 cm of all 3 coronary arteries • Non-flow-limiting stenoses not intended for PCI were identified with the following site-assessed features:
PROSPECT ABSORB: BVS + GDMT Safe Effective for Vulnerable
· PROSPECT ABSORB was an investigator-sponsored multicenter single-blinded agressive-treatment-controlled randomized trial that was embedded into the PROSPECT II …
Temps de Lecture Adoré: 4 mins